scholarly journals Predicting EQ-5D Index Scores from the PROMIS-29 Profile for the United Kingdom, France, and Germany

2020 ◽  
Author(s):  
Christoph Paul Klapproth ◽  
Jan van Bebber ◽  
Christopher J. Gibbons ◽  
Jose M Valderas ◽  
Leplege Alain ◽  
...  
Keyword(s):  
United Kingdom ◽  
Health Utility ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Order Effects ◽  
The United Kingdom ◽  
Life Years ◽  
Patient Reported ◽  
Reported Health ◽  
The Uk

Abstract Background: EQ-5D health utility (HU) scores are commonly used in health economics to compute quality-adjusted life years (QALYs). EQ-5D scores, which are country-specific, can be derived directly or by mapping from self-reported health-related quality of life (HRQoL) scales such as the PROMIS-29 profile. The PROMIS-29 from the Patient Reported Outcome Measures Information System is a comprehensive assessment of self-reported health with excellent psychometric properties. We sought to find optimal models for predicting EQ-5D scores from the PROMIS-29 in the United Kingdom, France, and Germany and compared the prediction performances with that of a US model.Methods: We collected EQ-5D-5L and PROMIS-29 profiles and three samples representative of the general populations in the UK (n=1,509), France (n=1,501), and Germany (n=1,502). We used stepwise regression with backward selection to find the best models to predict the EQ-5D score from all seven PROMIS-29 domains. We investigated the agreement between the observed and predicted EQ-5D scores in all three countries using various indices for the prediction performance, including Bland-Altman plots to examine the performance along the HU continuum.Results:The EQ-5D index scores were best predicted in Germany (RMSEGER = 0.10, MAEGER = 0.06), followed by France (RMSEFR = 0.11, MAEFR = 0.08) and the UK (RMSEUK = 0.12, MAEUK = 0.09). The Bland-Altman plots show that the inclusion of higher-order effects reduced the underprediction of low HU scores.Conclusions: Our models provide a valid method to predict EQ-5D-5L index scores from the PROMIS-29 for the UK, France, and Germany.

scholarly journals Predicting EQ-5D-3L index value from the PROMIS-29 profile for the United Kingdom, France, and Germany

2020 ◽  
Author(s):  
Christoph Paul Klapproth ◽  
Jan van Bebber ◽  
Christopher J. Sidey-Gibbons ◽  
Jose M Valderas ◽  
Alain Leplege ◽  
...  
Keyword(s):  
United Kingdom ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Order Effects ◽  
Health State ◽  
The United Kingdom ◽  
Life Years ◽  
Patient Reported ◽  
Reported Health ◽  
The Uk

Abstract Background: EQ-5D health state utilities (HSU) are commonly used in health economics to compute quality-adjusted life years (QALYs). The EQ-5D, which is country-specific, can be derived directly or by mapping from self-reported health-related quality of life (HRQoL) scales such as the PROMIS-29 profile. The PROMIS-29 from the Patient Reported Outcome Measures Information System is a comprehensive assessment of self-reported health with excellent psychometric properties. We sought to find optimal models predicting the EQ-5D from the PROMIS-29 in the United Kingdom, France, and Germany and compared the prediction performances with that of a US model.Methods: We collected EQ-5D-5L and PROMIS-29 profiles and three samples representative of the general populations in the UK (n=1,509), France (n=1,501), and Germany (n=1,502). We used stepwise regression with backward selection to find the best models to predict the EQ-5D from all seven PROMIS-29 domains. We investigated the agreement between the observed and predicted EQ-5D in all three countries using various indices for the prediction performance, including Bland-Altman plots to examine the performance along the HSU continuum.Results: The EQ-5D was best predicted in France (nRMSEFRA = 0.075, nMAEFRA = 0.052), followed by the UK (nRMSEUK = 0.076, nMAEUK = 0.053) and Germany (nRMSEGER = 0.079, nMAEGER = 0.051). The Bland-Altman plots show that the inclusion of higher-order effects reduced the overprediction of low HSU scores.Conclusions: Our models provide a valid method to predict the EQ-5D from the PROMIS-29 for the UK, France, and Germany.

scholarly journals Predicting EQ-5D-5L crosswalk from the PROMIS-29 profile for the United Kingdom, France, and Germany

2020 ◽  
Author(s):  
Christoph Paul Klapproth ◽  
Jan van Bebber ◽  
Christopher J. Sidey-Gibbons ◽  
Jose M Valderas ◽  
Alain Leplege ◽  
...  
Keyword(s):  
United Kingdom ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Order Effects ◽  
Health State ◽  
The United Kingdom ◽  
Life Years ◽  
Patient Reported ◽  
Reported Health ◽  
The Uk

Abstract Background: EQ-5D health state utilities (HSU) are commonly used in health economics to compute quality-adjusted life years (QALYs). The EQ-5D, which is country-specific, can be derived directly or by mapping from self-reported health-related quality of life (HRQoL) scales such as the PROMIS-29 profile. The PROMIS-29 from the Patient Reported Outcome Measures Information System is a comprehensive assessment of self-reported health with excellent psychometric properties. We sought to find optimal models predicting the EQ-5D-5L crosswalk from the PROMIS-29 in the United Kingdom, France, and Germany and compared the prediction performances with that of a US model.Methods: We collected EQ-5D-5L and PROMIS-29 profiles and three samples representative of the general populations in the UK (n=1,509), France (n=1,501), and Germany (n=1,502). We used stepwise regression with backward selection to find the best models to predict the EQ-5D-5L crosswalk from all seven PROMIS-29 domains. We investigated the agreement between the observed and predicted EQ-5D-5L crosswalk in all three countries using various indices for the prediction performance, including Bland-Altman plots to examine the performance along the HSU continuum.Results: The EQ-5D-5L crosswalk was best predicted in France (nRMSEFRA = 0.075, nMAEFRA = 0.052), followed by the UK (nRMSEUK = 0.076, nMAEUK = 0.053) and Germany (nRMSEGER = 0.079, nMAEGER = 0.051). The Bland-Altman plots show that the inclusion of higher-order effects reduced the overprediction of low HSU scores.Conclusions: Our models provide a valid method to predict the EQ-5D-5L crosswalk from the PROMIS-29 for the UK, France, and Germany.

scholarly journals Predicting EQ-5D-5L crosswalk from the PROMIS-29 profile for the United Kingdom, France, and Germany

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Christoph Paul Klapproth ◽  
J. van Bebber ◽  
C. J. Sidey-Gibbons ◽  
J. M. Valderas ◽  
A. Leplege ◽  
...  
Keyword(s):  
United Kingdom ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Order Effects ◽  
Health State ◽  
The United Kingdom ◽  
Life Years ◽  
Patient Reported ◽  
Reported Health ◽  
The Uk

Abstract Background EQ-5D health state utilities (HSU) are commonly used in health economics to compute quality-adjusted life years (QALYs). The EQ-5D, which is country-specific, can be derived directly or by mapping from self-reported health-related quality of life (HRQoL) scales such as the PROMIS-29 profile. The PROMIS-29 from the Patient Reported Outcome Measures Information System is a comprehensive assessment of self-reported health with excellent psychometric properties. We sought to find optimal models predicting the EQ-5D-5L crosswalk from the PROMIS-29 in the United Kingdom, France, and Germany and compared the prediction performances with that of a US model. Methods We collected EQ-5D-5L and PROMIS-29 profiles and three samples representative of the general populations in the UK (n = 1509), France (n = 1501), and Germany (n = 1502). We used stepwise regression with backward selection to find the best models to predict the EQ-5D-5L crosswalk from all seven PROMIS-29 domains. We investigated the agreement between the observed and predicted EQ-5D-5L crosswalk in all three countries using various indices for the prediction performance, including Bland–Altman plots to examine the performance along the HSU continuum. Results The EQ-5D-5L crosswalk was best predicted in France (nRMSEFRA = 0.075, nMAEFRA = 0.052), followed by the UK (nRMSEUK = 0.076, nMAEUK = 0.053) and Germany (nRMSEGER = 0.079, nMAEGER = 0.051). The Bland–Altman plots show that the inclusion of higher-order effects reduced the overprediction of low HSU scores. Conclusions Our models provide a valid method to predict the EQ-5D-5L crosswalk from the PROMIS-29 for the UK, France, and Germany.

scholarly journals Trends in Type 1 Diabetes Mortality and Disability-Adjusted Life-Years in 27 European Countries and the United Kingdom: 1990–2017

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A463-A463
Author(s):  
Aurimas Kudzinskas ◽  
Andrew Alazawi ◽  
Will Hughes ◽  
Richard Goodall ◽  
Eleanor Harbinson ◽  
...  
Keyword(s):  
United Kingdom ◽  
Czech Republic ◽  
Mortality And Morbidity ◽  
The United Kingdom ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Recent Trends ◽  
Males And Females ◽  
The Uk

Abstract Background: Type 1 diabetes mellitus (T1DM) is a prevalent condition with significant morbidity and financial implications. This study aims to compare the temporal trends in T1DM mortality and morbidity across 27 European Union (EU) countries and the United Kingdom between 1990 and 2017. Methods: The Global Burden of Disease Study database was used to extract T1DM age-standardized mortality rates (ASMR) and disability-adjusted life-years rates (DALYs) per 100,000 for 27 EU countries and the United Kingdom. Joinpoint regression analysis was used to interpret trends. Results: All countries, excluding males from the Czech Republic (+28.5%), had relative reductions in ASMR between 1990 and 2017. The largest relative reductions in ASMR between 1990 and 2017 were observed in Slovenia for both males and females (-75.9% and -87.9%, respectively). The smallest relative reductions in ASMR between 1990 and 2017 were seen in Malta for males (-5.9%) and Czech Republic for females (-12.5%). For all years from 1999 to 2017, males in all countries had higher T1DM ASMRs compared to females. Similarly, T1DM DALYs have decreased across all countries excluding males from the Czech Republic and Malta (+10.4% and +5.3%, respectively). The largest relative reductions in DALYs between 1990 and 2017 were observed in Poland for both males and females (-46.4% and -70.4%, respectively). The smallest relative reductions in DALYs were seen in Greece for both males and females (-4.1% and -17.0%, respectively). From all years from 2006 to 2017, males in all countries had higher T1DM DALYs compared to females. Joinpoint regression analysis demonstrated that over the time period covered by the most recent trends (2013/14–2017), small increases in T1DM ASMRs were observed in Malta, Germany, and Denmark, for males, and in the UK, Netherlands, Germany, and Denmark for females. Furthermore, the UK also observed increases in DALY rates for both males and females between 2013 and 2017 (estimated annual percentage increases: males +0.6%, females +0.5%). Discussion: We identified improvements in both the mortality and morbidity from T1DM in European Union Countries between 1990 and 2017. Both the incidence and prevalence of T1DM is known to be increasing, therefore the observed improvements in mortality and morbidity reflect continent wide improvements in disease management. Our data do suggest, however, that the improvements in mortality and DALYs appear to be plateauing in the UK over the time periods covered by the most recent trends.

Joint assessment in haemophilia – current physiotherapist practice in the UK

2014 ◽  
Vol 1 (3) ◽  
pp. 9-13 ◽  
Author(s):  
Paul McLaughlin ◽  
Melanie Bladen ◽  
Mike Holland ◽  
Kate Khair
Keyword(s):  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Scoring Methods ◽  
Patient Reported ◽  
Subsequent Discussion ◽  
Joint Health ◽  
The Uk ◽  
The Relationship ◽  
Joint Assessment

Abstract Aim: UK guidelines recommend regular assessment of joint status in children with haemophilia using a standardised tool performed by haemophilia physiotherapists. We surveyed UK physiotherapists working in haemophilia care regarding their current practice with respect to joint scoring. Methods: A survey was posted on SurveyMonkey and all haemophilia physiotherapists practising in the UK were invited to respond. Responses were analysed and discussed at a roundtable meeting attended by invited physiotherapists and specialist haemophilia nurses. Results: In all, responses were received from 29 of the estimated 37 physiotherapists in the UK who see haemophilia patients. Both the survey and subsequent discussion reflected agreement that joint scoring offers a valuable tool to clinicians, but that better ways of assessing joint health were needed. There was enthusiasm for combining joint scoring with systematic and validated patient-reported outcome measures. Conclusion: Greater understanding is needed of the relationship between joint scores and measures of physical function and quality of life.

scholarly journals Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018

2021 ◽  
Author(s):  
Alice Morgan ◽  
Sally Hartmanis ◽  
Emmanuel Tsochatzis ◽  
Philip N. Newsome ◽  
Stephen D. Ryder ◽  
...  
Keyword(s):  
United Kingdom ◽  
Liver Disease ◽  
Economic Impact ◽  
Disease Burden ◽  
Economic Costs ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Steatohepatitis ◽  
The United Kingdom ◽  
Life Years ◽  
The Uk

Abstract Background and aims Non-alcoholic steatohepatitis (NASH) – a progressive subset of non-alcoholic fatty liver disease (NAFLD) – is a chronic liver disease that can progress to advanced fibrosis, cirrhosis, and end-stage liver disease (ESLD) if left untreated. Early-stage NASH is usually asymptomatic, meaning a large proportion of the prevalent population are undiagnosed. Receiving a NASH diagnosis increases the probability that a patient will receive interventions for the purpose of managing their condition. The purpose of this study was to estimate the disease burden and economic impact of diagnosed NASH in the United Kingdom (UK) adult population in 2018. Methods The socioeconomic burden of diagnosed NASH from a societal perspective was estimated using cost-of-illness methodology applying a prevalence approach. This involved estimating the number of adults with diagnosed NASH in the UK in a base period (2018) and the economic and wellbeing costs attributable to diagnosed NASH in that period. The analysis was based on a targeted review of the scientific literature, existing databases and consultation with clinical experts, health economists and patient groups. Results Of the prevalent NASH population in the UK in 2018, an estimated 79.8% were not diagnosed. In particular, of the prevalent population in disease stages F0 to F2, only 2.0% (F0), 2.0% (F1) and 16.5% (F2), respectively, were diagnosed. Total economic costs of diagnosed NASH in the UK ranged from £2.3 billion (lower prevalence scenario, base probability of diagnosis scenario) to £4.2 billion (higher prevalence scenario, base probability of diagnosis scenario). In 2018, people with NASH in the UK were estimated to experience 94,094 to 174,564 disability-adjusted life years (DALYs) overall. Total wellbeing costs associated with NASH in 2018 were estimated to range between £5.6 to £10.5 billion. Conclusion The prevention and appropriate management of adult NASH patients could result in reduced economic costs and improvements in wellbeing.

Sign in / Sign up

Export Citation Format

Share Document